All News
“The differences and similarities between axial disease in psoriatic arthritis vs axial spondyloarthritis is just at the cusp of discovery” Nigil Haroon at session 6S403 @RheumNow #ACR21
Dr. Antoni Chan synovialjoints ( View Tweet)
My first video for #ACR21 for @RheumNow, discussing #SickLeave, #WorkParticipation and #WorkDisability in patients with #SpA, with a focus on abstracts 0380 and 0381 by @ElenaNikiUK
#axspa #spondyloarthritis #arthritis #qualityoflife
Watch it here👇🏼
https://t.co/MEQ4wkFxrx
Mrinalini Dey DrMiniDey ( View Tweet)
Torgutalp et al.
⭐️Included Early axSpA - 166 nr-axSpA (symptom duration ≤5 y) and 135 with r-axSpA (symptom duration ≤10 y) from German Cohort
⭐️Assessed TNFI use over 2 years and has shown🔽 in radiographic sacroiliitis progression.
Abst#0451 #ACR21 @RheumNow #ACRBest https://t.co/xP0wMLSyGw
swethaann23 swethaann23 ( View Tweet)
IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers?
⬆️IL-22 in AxSpA vs. controls
⭐️IL-22 did not correlate w/ mSASSS, BASADI, ASDAS, CRP
Abs#385
#ACR21
@RheumNow https://t.co/hNtStAluJH
Robert B Chao, MD doctorRBC ( View Tweet)
2 year study of AxSpA pts in clinical remission who tapered TNFi.
⭐️52% successfully tapered to either 2/3, 1/2 or 1/3 dose
⭐️Baseline physician global score independent predictor of successful tapering
Abs#364
#ACR21
@RheumNow
https://t.co/9Kti5JGMYr https://t.co/y1Uj2dTABC
Robert B Chao, MD doctorRBC ( View Tweet)
@ericdeinmd @RheumNow *TICOSPA
IMO, more an issue of poor tools for activity monitoring and insufficiently diverse toolbox. Works in RA as lots of choices and good activity measures. Until AxSpa has those, don’t see how we hope to meet “tight control”.
Ethan Craig rheumecraig ( View Tweet)
Irish registry of AS pts included 76 women who were pregnant
⭐️58% uncomplicated, 41.9% complicated, 11% multiple complications
⭐️frequency of miscarriage ⬆️
⭐️complications included C-section, preterm, NICU admission
#ACR21
@RheumNow
Abs#369 https://t.co/90dolEeTIw
Robert B Chao, MD doctorRBC ( View Tweet)
Self-monitoring app for AxSpA pts
⭐️adherence over 6 months poor 😔
⭐️high disease activity and older age related to ⬆️frequency of reporting
Abs#373
#ACR21
@RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Year in Review: TICOPSA - tight control treat to target in AxSpa does not meet primary endpoint, but favorable secondary outcomes. Was the control group at academic center already receiving good tight control? @Rheumnow
Eric Dein ericdeinmd ( View Tweet)
#ACR21 #ACRbest @RheumNow
Abst#0366 by Garrido-Cumbrera et al. looked at shows that three out of four European axSpA patients have difficulty in finding a job.
swethaann23 swethaann23 ( View Tweet)
T2T in AxSpA? ASDAS-qCRP & ASDAS-CRP showed an almost perfect agreement w/ regard to dz activity categories (96%.) Quick ASDAS-qCRP can be used in real time to make clinical decisions. Abs 0374 #ACR21 #RheumNow @RheumNow https://t.co/opOyedQUaZ https://t.co/aeUEsW9HsX
Dr. Rachel Tate uptoTate ( View Tweet)
Biologic dose tapering in #axialspondyloarthritis in 52% of patients if criteria are met (BASDAI)< 40, physician global score< 40 and no signs of disease activity the previous year, escalation to previous dose if there is a flare @RheumNow #ACR21 Abst#0364 https://t.co/4GntJ6jS11
Dr. Antoni Chan synovialjoints ( View Tweet)
Rare co-existence of FMF & axSpA significantly lowered age of axSpA symptom onset. Radiographic changes in FMF+axSpA suggested worse disease. Rate of amyloidosis and hip involvement were higher in FMF+axSpA pts. Abs 0378 #ACR21 #RheumNow @RheumNow https://t.co/lUmn3A90Ob https://t.co/n3kj8GcV1i
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 @RheumNow
Abst#0450 Hwang et al. from the PSOAS cohort analyzed 1618 radiographs between 2002-2017
⭐️Higher spinal disease: Male gender; longer disease duration; smoking
⭐️🔼Disease progression 🔼CRP levels
⭐️🔽Disease progression with time-varying TNFI use https://t.co/XsKp28HOxz
swethaann23 swethaann23 ( View Tweet)
AxSpA pts share a gut microbiome signature with Crohn's disease and anterior uveitis pts
⬇️Blautia
⬆️Veillonella and Lactobacillus
⭐️SpA pts uniquely enriched in Collinsella
Abs#0062 #ACR21 @RheumNow #ACRBest
https://t.co/sdlHxNbhr8 https://t.co/r8eG9c9vwa
Robert B Chao, MD doctorRBC ( View Tweet)
Early axSpA DESIR: higher dz activity & worse function independently assoc'd w/ ^ hazard of Work Disability vs SES. Dz severity strong predictor of adverse work outcome despite advanced therapeutic strategies in axSpA. Abs 0381 #ACR21 #RheumNow @RheumNow https://t.co/Lc3yUgXvw6
Dr. Rachel Tate uptoTate ( View Tweet)
Is it time to consider targeting gut microbiome for treatment of AS?
Large study identified:
⭐️Ruminococcus torques associated with FUT2 gene influences risk of developing AS
Abs#0068
https://t.co/E1hL18KZbQ
#ACR21
#ACRBest
@RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Possible disease activity biomarkers in axSpA? Neutrophil lymphocyte ratio (NLR) & platelet lymphocyte ratio (PLR) along w/ PROs may be helpful to measure dz activity clinically. More studies needed for proof of concept. Abs 0384 #ACR21 #RheumNow @RheumNow https://t.co/ZXyQHNzqz7 https://t.co/va5fBR9Gnk
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 @RheumNow
Abst#0370 by Afinogenova et al.
138 PCP surveyed on Chronic back pain evaluation
▶️58% rarely assess for IBP
▶️40% not comfortable diagnosing AS
▶️70% not comfortable diagnosing axSpA
Contributing to a lack of referral to rheumatology and delay in diagnosis.
swethaann23 swethaann23 ( View Tweet)
Serum IL-22 levels elevated in axSpA pts in Israeli study. Possible independent biomarker for the differentiation of AxSpA from its non-inflammatory mimickers? Possible target for treatment? Further studies needed. Abs 0385 #ACR21 #RheumNow @RheumNow https://t.co/AUwZFJTlnq https://t.co/WSZ2WjW45W
Dr. Rachel Tate uptoTate ( View Tweet)
